Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: atrial fibrillation + new tool + new  Related to the article below (Last Update: 7/8/2008)

NICE tool will create inequality
Healthcare Republic - Jul 7, 2008
... rheumatoid arthritis, renal disease and atrial fibrillation to the original QRISK criteria. To test it, both QRISK2 and the modified Framingham tool ...
Atrial Fibrillation Data From UK Study Evaluating the Cardima EP ...
CNNMoney.com - Jun 12, 2008
Identifying new patient treatment options for AF that are safe and effective is an important public health issue for the UK and many countries around the ...OTC:CADM
Cardima's Surgical Ablation Technology in the News
CNNMoney.com - Jun 17, 2008
Dr. Poa's lecture, "Surgery for lone atrial fibrillation," included his experience with the Cardima Surgical Ablation System. ...OTC:CADM
Atrial Fibrillation Data From UK Study Evaluating the Cardima EP ...
istockAnalyst.com, OR - Jun 12, 2008
Identifying new patient treatment options for AF that are safe andeffective is an important public health issue for the UK and many countriesaround the ...OTC:CADM
Cardiologychannel Offers Heart Patients New Opportunities for ...
PR Web (press release), WA - Jun 17, 2008
For example, one person who was recently diagnosed with atrial fibrillation writes, "(I've) been looking for a Forum like this for ages. ... great to get on ...
Cardima's Surgical Ablation Technology in the News
istockAnalyst.com, OR - Jun 17, 2008
Dr. Poa's lecture, "Surgery for lone atrial fibrillation," included hisexperience with the Cardima Surgical Ablation System. The Cardima Systemwas presented ...OTC:CADM
Letting the genome out of the bottle: Unraveling the genetics of ...
TheHeart.Org, NY - Jun 23, 2008
One is the identification of a major genomic maker for atrial fibrillation (AF), 4q25 [7], and there have also been three GWAS identifying seven new genetic ...
Improving Evidence-Based Care for Heart Failure Patients
Medscape (subscription) - Jun 20, 2008
The HF guidelines have evolved and a number of new therapies for HF have recently become Class I recommendations. It can be difficult for the practicing ...
Get fit in the garden
Toronto Sun,  Canada - Jun 22, 2008
His new book, Get Fit Through Gardening, offers advice, tips and tools for better health and features a fitness plan designed to save backs and knees. ...
Source: Google News

[PDF] New ideas about atrial fibrillation 50 years on -
S Nattel? - Nature, 2002 - cardio.bjmu.edu.cn
... For over 50 years, the prevailing model of atrial fibrillation involved multiple
simultaneous re-entrant waves, but in light of new discoveries this hypothesis ...
-

A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic … -
K Nademanee, J McKenzie, E Kosar, M Schwab, B … - Journal of the American College of Cardiology, 2004 - Am Coll Cardio Found
... in a more organized rhythm of a new macroreentrant circuit ... of atrial excitation during
atrial fibrillation in humans ... mapping for arrhythmia ablation: Tool or toy ...

… of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a … -
CP Appleton, LK Hatle, RL Popp - Journal of the American College of Cardiology, 1988 - Am Coll Cardio Found
... ventricular diastolic function: new insights from ... of Patients With Isolated Atrial
Fibrillation Circulation, November ... monitoring: an operative tool to evaluate ...

A new system for catheter ablation of atrial fibrillation. -
H Calkins, J Hall, K Ellenbogen, G Walcott, M … - Am J Cardiol, 1999 - ncbi.nlm.nih.gov
... now being focused on developing new technologies to ... of catheter ablation of atrial
fibrillation and, ultimately ... routine use of this therapeutic tool can become ...

Non-invasive assessment of the atrial cycle length during atrial fibrillation in man: introducing, … -
M Holm, S Pehrson, M Ingemansson, L Sornmo, R … - Cardiovascular Research, 1998 - cardiovascres.oxfordjournals.org
... Objectives: Atrial fibrillation (AF) in man has previously been ... and globally with
the degree of atrial organization, with ... AF, we have developed a new method for ...

Intraoperative left atrial ablation (for atrial fibrillation) using a new argon cryocatheter: early … -
N Doll, BB Kiaii, AM Fabricius, J Bucerius, P … - The Annals of Thoracic Surgery, 2003 - Soc Thorac Surgeons
... This report describes our early experience in treatment of patients with chronic
or paroxysmal atrial fibrillation with a new tool for left atrial cryoablation ...

… Valve/Ridge on Atrial Flutter Relevance to Catheter Ablation of the Septal Isthmus and a New … -
H Nakagawa, R Lazzara, T Khastgir, KJ Beckman, JH … - Circulation, 1996 - Am Heart Assoc
... 235?59 ms (Table 2 ). Sustained atrial fibrillation ( 60 seconds ... 2 patients after
ablation of atrial flutter (Table 3 ... in this window] [in a new window], Figure 9 ...

A new treatment for atrial fibrillation based on spectral analysis to guide the catheter RF-ablation -
JC Pachon M, EI Pachon M, JC Pachon M, TJ Lobo, MZ … - Europace, 2004 - Eur Heart Rhythm Assoc
... By using this tool, we have found two types of atrial ... ablation of pulmonary vein
ostia: a new anatomic approach for curing atrial fibrillation. ...

… Cardioversion With Epicardial Wire Electrodes: New Treatment of Atrial Fibrillation After Open Heart … -
A Liebold, A Wahba, DE Birnbaum - Circulation, 1998 - Am Heart Assoc
... cardioversion versus medical treatment for the termination of atrial fibrillation
after CABG Ann ... page, Journal Watch Cardiology Home page A New Tool for Managing ...

[CITATION] Analysis of Heart Rate Variability Five Minutes Before the Onset of Paroxysmal Atrial Fibrillation -
M FIORANELLI, M PICCOLI, GM MILETO, F SGRECCIA, P … - Pacing and Clinical Electrophysiology, 1999 - Blackwell Synergy
... Neural Aspects of Paroxysmal Atrial Fibrillation Atrial Fibrillation: Mechanism
and ... Falk, P Podrid (ed.): New York, NY ... heart rate variability: A tool to explore ...

Source: Google Scholar
 
 

New Tool Being Tested To Halt Recurrence Of Atrial Fibrillation - Benefits Could Include Shorter Procedure Time And Improved Effectiveness

Article Date: 14 Dec 2006 - 0:00 PST
Clinical researchers at the University of Pennsylvania Health System are starting a trial utilizing a new mechanism to treat the heart when its electrical pulses essentially short-circuit, referred to as atrial fibrillation (A-Fib).

The biggest problem physicians run into with current therapies to cope with electrical rhythmic pumping problems in the heart, namely pulmonary vein isolation procedures, is that up until now, they've had to deliver the energy bursts to the tissue in a dot-by-dot catheter ablation procedure around the veins, almost like a string of pearls. "That can cause swelling, and when that swelling goes down, you may still have viable tissue left behind, gaps, where the electricity can still conduct itself or get through," explains David Callans, MD, director of the electrophysiology laboratory at the Hospital of the University of Pennsylvania and principal investigator of this study. "Now we have a mechanism to construct this barricade of lesions, to do an entire circular ablation, minimizing the potential for gaps behind in the pulmonary veins."

Article continues below and (thank you)
 
Cardiac electrophysiologists at Penn are now using a high intensity focused ultrasound (HIFU) ablation system. It's the first to deliver energy bursts forward in a complete circle, all at once, from outside of the vein. This invasive procedure is done in the lab with balloon catheters while the patient is awake but sedated.

Electrophysiologists use ablation procedures (involving intense heat on the area of the heart causing the rhythmic pumping problems) to turn pulmonary vein tissue into scar tissue so that it can no longer conduct electricity. When this is done in several locations, it can effectively stop the symptoms of atrial fibrillation, which affects as many as five million Americans. "Since this new system sits outside of the vein, and delivers energy forward rather than immediately around it, there is no damage to the inside of the vein. This maintains a normal blood flow. Plus, this new system could shorten the ablation procedure time which currently takes about four hours," adds Callans.

Penn -- which is the only trial site in Pennsylvania, and one of 15 nationally -- is now recruiting volunteers for the HIFU ablation system trial. If you're interested in participating, call 215-662-6052. This is a randomized trial in which some participants will receive ablation treatment with the HIFU system made by ProRhythm, Inc. while others will be treated with anti-arrhythmic medication. The patients in this trial must be symptomatic and the atrial fibrillation must start and stop on its own (it is not persistent).

Penn Medicine, which has one of the largest cardiac electrophysiology programs in the country, has been doing atrial fibrillation ablation procedures for the last several years. Callans states, "Ablation is definitely the future for treatment of atrial fibrillation. Everything else we currently use to treat A-Fib is flawed. So the ablation procedure itself has to improve, become more effective and safer. And one way we can do this is on the technology front by developing better tools. This trial may be a big part of that."

-- More information on Penn Cardiac Care
-- David Callans, MD -- on-line bio
-- More information on ProRhythm, Inc.

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
 

Promising Drug Combinations For Sleeping Sickness



Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.

African trypanosomiasis, or sleeping sickness affects many tens of thousands of people each year in sub-Saharan Africa and is a serious disease for which there are few treatment options. The most commonly used drug, Melarsoprol, is highly toxic. MSF and Epicentre jointly carried out a trial that started in 2001 in Uganda to evaluate the efficacy and safety of three drug combinations for this disease. The aim was to find out if any of these combinations would provide a viable treatment option for patients with second-stage sleeping sickness, where infection has reached the brain and prognosis is normally very poor. In the trial the drug combinations compared were melarsoprol-nifurtimox, melarsoprol-eflornithine, and nifurtimox-eflornithine. However, once 54 patients had been recruited (435 were planned), it was obvious that the death rate was much higher amongst individuals receiving one of the combinations, so the trial was stopped.

In the trial, the cure rate for nifurtimox-eflornithine was over twice that for melarsoprol-nifurtimox and substantially higher than that for melarsoprol-eflornithine. The rates of adverse events were also lower for patients treated with nifurtimox-eflornithine. These findings are encouraging and suggest that the nifurtimox-eflornithine combination has potential as a future therapy for second-stage African trypanosomiasis, and should be evaluated further in clinical trials.

###

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS CLINICAL TRIALS (http://www.plosclinicaltrials.org/) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Clinical Trials are open access. Everything is immediately available without cost to anyone, anywhere - to read, download, redistribute, include in databases, and otherwise use - subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Citation: Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin Trials 1(8): e39.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pctr.0010039

CONTACT: Gerardo Priotto
Epicentre
42-bis Bvd. Richard-Lenoir
Paris, 750011
France

About PLoS Clinical Trials

PLoS Clinical Trials is an open access, freely available international medical journal. The journal's goal is to broaden the scope of clinical trials reporting by peer-reviewing and publishing the results of all randomized trials that are ethically and scientifically sound, irrespective of the trial's outcome. PLoS Clinical Trials aims to increase the accuracy and completeness of the evidence base for clinical decision-making. For more information see http://www.plosclinicaltrials.org/.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org/

Contact: Sarah Clark
Public Library of Science
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page